Pharmacokinetic Interactions Between Statins and Fibrates
- 7 November 2005
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 96 (9) , 44-49
- https://doi.org/10.1016/j.amjcard.2005.08.007
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statinThe American Journal of Cardiology, 2005
- Risk of adverse events with fibratesThe American Journal of Cardiology, 2004
- Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in HumansThe Journal of Clinical Pharmacology, 2004
- Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapyPharmacoepidemiology and Drug Safety, 2004
- Role of fibrates in reducing coronary risk: a UK ConsensusCurrent Medical Research and Opinion, 2004
- Controversy surrounding the safety of cerivastatinExpert Opinion on Drug Safety, 2002
- Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy VolunteersThe Journal of Clinical Pharmacology, 2000
- Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients: Are the Statins Mechanistically Similar?Pharmacology & Therapeutics, 1998
- Pharmacokinetics of the combination of fluvastatin and gemfibrozilThe American Journal of Cardiology, 1995
- Efficacy and long-term adverse effect pattern of lovastatinThe American Journal of Cardiology, 1988